Why ALVIZON™?

  • ALVIZON™ (fludrocortisone acetate) represents a novel class of agents for the treatment of eye disease.
  • Dry-AMD, and its end-stage, Geographic Atrophy (GA), involve inflammation and retinal pigmented epithelium (RPE) loss.
  • ALVIZON™’s unique mode of action targets nuclear receptors influencing blood-retinal barrier function and inflammatory pathways, including complement.
  • In Phase I and Phase IIa clinical studies, there was no evidence of sustained IOP rise, no evidence of induced cataractogenesis or retinal toxicity.
  • Data from the Phase IIa study suggest that a three-monthly intravitreal injection is effective.
  • ALVIZON™ also demonstrated significant inhibition of GA lesion expansion.